Voyager Therapeutics officially completed its initial public offering on the NASDAQ stock exchange under the ticker symbol VYGR on November 11, 2015. During its market debut, the biotechnology enterprise issued shares to raise capital intended to fund its expanding pipeline of adeno-associated virus-based gene therapies targeting central nervous system disorders, marking its transition into a publicly traded corporate entity subject to public market disclosures.